A
Aura Biosciences
Developing a new class of therapies to target and destroy cancer cells selectively
About Aura Biosciences
Aura Biosciences is a biotechnology company focused on developing a new class of therapies designed to target and selectively destroy tumor cells. The company's lead program, AU-011, is aimed at treating ocular melanoma, a rare and aggressive eye cancer. This program has been developed in collaboration with the National Cancer Institute (NCI) and has received orphan drug status from the US Food and Drug Administration (FDA).
Aura Biosciences operates in the oncology market, specifically targeting cancers that are difficult to treat with conventional methods. The company's innovative approach involves light-activated therapies that can precisely target solid tumors and metastases without damaging surrounding healthy tissue. This precision reduces the invasiveness and toxicity typically associated with cancer treatments.
The business model of Aura Biosciences involves the development and commercialization of its proprietary therapies. The company generates revenue through the sale of its therapeutic products, once they receive regulatory approval, and potentially through partnerships and licensing agreements with other pharmaceutical companies.
Aura Biosciences serves patients suffering from ocular melanoma and potentially other cancers in the future as its technology platform expands. The company is committed to advancing its clinical trials and bringing its innovative treatments to market to improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Cambridge, United States
- Listing
- IPO 2021
- Employees
- 129
- Open positions
- None listed
- Dealroom signal
- 85.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Technology
- Deep Tech, Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $299M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Aug 2025 | $75M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$112M | — |
| 2025 | $0 | — | −$112M | — |
| 2024 | $0 | — | −$95M | — |
| 2023 | $0 | — | −$84M | — |
| 2022 | $0 | — | −$60M | — |
| 2021 | $0 | — | −$35M | — |
| 2020 | $0 | — | −$21M | — |
Growth signals
Latest recorded traffic for Aura Biosciences is 5.8K monthly website visits, up 16% over the last three months. Aura Biosciences's team grew 4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Advent Life Sciences
Ysios Capital
Henri Termeer
Alexandria Venture Investments
Li-Cor
Chiesi Ventures
Advent Partners
Series B and later12 investors entered at this stage
Arix Bioscience
Lundbeckfonden- ALADVENT LIFE SCIENCES LLP
Columbus Venture Partners
Lundbeckfonden Ventures
Medicxi
Pappas Capital
Citadel
Matrix Capital Management
Adage Capital
Rock Springs Capital
Velocity Capital Fintech Ventures
Other known investors1 additional known investor
National Center for Complementary and Integrative Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aura Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aura Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.